263 related articles for article (PubMed ID: 29549331)
1. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Pastor Fernández A; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson AL; Johansson L; Färnegårdh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Håkansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Laín S
Nat Commun; 2018 Mar; 9(1):1107. PubMed ID: 29549331
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology.
Ladds MJGW; Popova G; Pastor-Fernández A; Kannan S; van Leeuwen IMM; Håkansson M; Walse B; Tholander F; Bhatia R; Verma CS; Lane DP; Laín S
J Biol Chem; 2020 Dec; 295(52):17935-17949. PubMed ID: 32900849
[TBL] [Abstract][Full Text] [Related]
3. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
Popova G; Ladds MJGW; Johansson L; Saleh A; Larsson J; Sandberg L; Sahlberg SH; Qian W; Gullberg H; Garg N; Gustavsson AL; Haraldsson M; Lane D; Yngve U; Lain S
J Med Chem; 2020 Apr; 63(8):3915-3934. PubMed ID: 32212728
[TBL] [Abstract][Full Text] [Related]
5. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
6. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
7. Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
Hubackova S; Davidova E; Boukalova S; Kovarova J; Bajzikova M; Coelho A; Terp MG; Ditzel HJ; Rohlena J; Neuzil J
Cell Death Dis; 2020 Feb; 11(2):110. PubMed ID: 32034120
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
9. Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.
Boukalova S; Hubackova S; Milosevic M; Ezrova Z; Neuzil J; Rohlena J
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165759. PubMed ID: 32151633
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
Berber B; Doluca O
Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods.
Higgins WT; Vibhute S; Bennett C; Lindert S
J Chem Inf Model; 2024 Jan; 64(2):435-448. PubMed ID: 38175956
[TBL] [Abstract][Full Text] [Related]
13. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.
Sykes DB
Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938
[No Abstract] [Full Text] [Related]
14. Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase.
Liu Z; Hu Q; Wang W; Lu S; Wu D; Ze S; He J; Huang Y; Chen W; Xu Y; Lu W; Huang J
Biochem Pharmacol; 2020 Jul; 177():114000. PubMed ID: 32353424
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
Vyas VK; Variya B; Ghate MD
Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
[TBL] [Abstract][Full Text] [Related]
17. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
18. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
19. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
20. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
